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Abstract
Severe inflammation has been shown to induce a shedding of the endothelial glycocalyx (EGX). Inflammatory cytokines, such as
tumor necrosis factor a (TNF-a), impede the thickness of the EGX. While a controlled inflammatory reaction occurs already in
normal pregnancy, women with hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome had an exaggerated
inflammatory response. This study investigates the shedding of the glycocalyx during normal pregnancy and in women with HELLP
syndrome. Glycocalyx components (syndecan 1, heparan sulfate, and hyaluronic acid) were measured in serum of healthy women
throughout pregnancy (4 time points, n ¼ 26), in women with HELLP syndrome (n ¼ 17) before delivery and in nonpregnant
volunteers (n ¼ 10). Serum concentrations of TNF-a and soluble TNF-a receptors (sTNF-Rs) were assessed once in all 3 groups.
Syndecan 1 serum concentrations constantly rose throughout normal pregnancy. Immediately before delivery, a 159-fold increase
was measured compared to nonpregnant controls (P < .01). Even higher amounts were observed in patients with HELLP prior to
delivery (median 12 252 ng/mL) compared to healthy women matched by gestational age (median 5943 ng/mL; P < .01). Relevantly,
increased serum levels of heparan sulfate, hyaluronic acid, and sTNF-Rs were only detected in patients with HELLP (P < .01).
These findings suggest that considerable amounts of syndecan 1 are released into maternal blood during uncomplicated preg-
nancy. The HELLP syndrome is associated with an even more pronounced shedding of glycocalyx components. The maternal
vasculature as well as the placenta has to be discussed as a possible origin of circulating glycocalyx components.
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Introduction
There is constantly growing scientific understanding of the
functionality of the endothelial glycocalyx (EGX), which coats
the luminal surface of blood vessels. The EGX consists of
extracellular domains of molecules such as transmembrane
syndecan 1 and membrane-bound glypicans, that both contain
covalently bound, highly negatively charged glycosaminogly-
cans (heparan sulfate and hyaluronic acid). In some regions
of the vascular bed, the EGX has proved to be even thicker
(500 nm) than the endothelial cells.1-4 A variety of physiologi-
cal properties has been ascribed to the EGX of which its vital
role for vascular integrity and its involvement in immunologi-
cal processes are certainly most striking.5-16 Animal studies
have confirmed that tumor necrosis factor a (TNF-a), usually
a proinflammatory mediator substance, can reduce the thick-
ness of the EGX.11,17 Experimental and clinical studies have
investigated the shedding of the EGX in severe sepsis.12,14,15,18
Nelson and coworkers even correlated these increases to
overall mortality and the antibacterial actions of plasma.14
Some of the physiological processes occurring throughout
normal pregnancy have been interpreted as a controlled
inflammatory reaction as well. Under pathological conditions,
for example, preeclampsia, this usually limited inflammatory
response can get out of control. In these cases, endothelial
dysfunction occurs, which involves various mediators (eg,
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TNF-a, interleukin [IL]-2, IL-6, and IL-8), cell adhesion
molecules, and leukocytes.19-21 Today, the syndrome of
hemolysis, elevated liver enzymes, and low platelets (HELLP
syndrome) is regarded to be associated with preeclampsia
and, besides its typical constellation of laboratory abnormal-
ities, can be accompanied by vascular leakage, disseminated
intravascular coagulation, and thrombocyte adhesion.22 These
pathomechanisms are also known to occur during severe sep-
sis and to be associated with a destruction of the EGX.23,24
However, a possible involvement of the EGX in physiological
or pathological processes during pregnancy has not yet
been investigated. This study aimed to determine the effect
of normal pregnancy and HELLP syndrome on the shedding
of the EGX. Moreover, serum concentrations of TNF-a and




Three groups of women were defined to participate in the study
1. Pregnant, otherwise healthy women with a gestational age
between weeks 10 and 14 of pregnancy (normal pregnancy
group: NP), n ¼ 26.
2. Pregnant women with a verified HELLP syndrome
(HELLP group: HG), n ¼ 17. HELLP syndrome was clas-
sified on the basis of platelet count nadir: class I:
<50  109/L, class II: 50  109/L to 100  109/L, class III
>100  109/L (Mississippi Triple Class System according
to Martin et al25). Elevated liver enzymes (aspartate ami-
notransferase or alanine transaminase >70 U/L) and
hemolysis have to be present in any case. To detect hemo-
lysis, haptoglobin serum levels were measured instead of
LDH because haptoglobin seems to be the more specific
indicator.22,26,27
3. Healthy female nonpregnant volunteers aged 27 to 38
years (laboratory control group [CG]), n ¼ 10. This group
was designed in order to establish normal ranges for serum
concentrations of EGX components. Group members were
recruited among the department’s medical stuff. Age
restriction was necessary in order to fit the mean age of the
study population as closely as possible.
All women were of European/Caucasian origin. The research
protocol was approved by the institutional review board and all
women gave written informed consent before enrolment.
Women with preexisting and gestational diabetes mellitus, pre-
existing arterial hypertension, acute or chronic infections, vas-
cular diseases, and/or chronic glucocorticoid therapy were
excluded from the study as well as women with prenatal infec-
tions and women requiring an emergency section, independent
of its cause. None of the women had been given heparin or
heparin-like drugs. However, 12 of 17 patients of the HG
received glucocorticoids before cesarean section to provide
lung maturity of the neonate.
The EGX Components
Syndecan 1, heparan sulfate and hyaluronic acid, each repre-
senting another part of the glycocalyx structure, were measured
in maternal serum.2 In the NP, blood samples were drawn at
weeks 12 + 2, 20 + 2, 30 + 3, 38 + 2 or directly after the
beginning of labor, if childbirth occurred unexpectedly before
week 38. In the HG, blood sampling took place immediately
before induction of anesthesia for cesarean section. There were
no spontaneous deliveries in the HG. In addition, blood sam-
ples were collected from 10 women of the CG. Samples were
allowed to clot for 30 minutes and afterward cautiously centri-
fuged (10 minutes at 3000 rpm). Serum was stored at 48C
within 15 minutes after the beginning of centrifugation. Com-
mercial enzyme-linked immunosorbent assay (ELISA) kits
were used to analyze serum samples according to the manufac-
turers’ manuals (Diaclone SAS, Besançon, France for syndecan
1; Echelon Biosciences Inc, Salt Lake City, Utah for hyaluronic
acid; and Seikagaku Corporation, Tokyo, Japan for heparan
sulfate). The intra-/interassay variability for the ELISA kits
was as follows (%): syndecan 1 3.6/5.7; heparan sulfate 6.4/
4.9; hyaluronic acid 7.1/5.0.
TNF-a and sTNF-Rs
Serum TNF-a was analyzed with a highly sensitive ELISA kit
(sensitivity 0.13 pg/mL, IBL International Corp, Hamburg,
Germany). Simultaneously, serum concentrations of sTNF-
R1 and sTNF-R2 were measured with another ELISA (Wuhan
EIAAB Science, Wuhan, China). The intra-assay variability for
the ELISA kits was as follows (%): TNF-a 9.6/9.8; sTNF-R1
5.4/8.9; and sTNF-R2 2.4/3.2. Groups, time points of measure-
ments, and blood processing were as described above for
‘‘EGX components’’ in the HG, CG, and in week 30 + 3 of
normal pregnancy.
Statistics
Mean, standard deviation of the mean, median, and 25th/75th
percentile were calculated for each target parameter. To test
normality, the Kolmogorov-Smirnov test was applied. Because
most of the data were not normally distributed, they are pre-
sented as median with 25th/75th percentile. To describe the
changes of EGX components, TNF-a and sTNF-Rs during the
course of normal pregnancy, a repeated measurement analysis
of variance (ANOVA) on ranks (Friedman test) followed by a
Nemenyi test was used. Women of the NP were only included
in this intragroup comparison if a complete set of blood sam-
ples was available (week 10-38; n ¼ 18).
In order to compare differences between laboratory values
measured in the NP and the HG, a one-way ANOVA on ranks
(Kruskal-Wallis test) was followed by Dunn’s test. The Spear-
man rank-order method was applied to work out relevant cor-
relations between target parameters.
The mean gestational age before delivery in the HG was
32.0 + 2.8 weeks. Therefore, we matched serum
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concentrations of TNF-a, sTNF-Rs, and EGX components of
women with HELLP syndrome to the values of healthy preg-
nant women at week 30 + 3 with gestational age being the
matching criterion. Matching was performed manually by a
blinded person using the ‘‘random order, nearest available
pair-matching method.’’28 In order to increase the number of
possible matching partners for the HG and to achieve a maxi-
mal congruency between groups in terms of the matching cri-
terion, every woman who had remained in the NP until week
30 was included in the matching procedure (n ¼ 22).
The difference between syndecan 1 serum concentrations
between HG and NP (week 30 + 3) was considered to be the
main outcome variable. After collecting samples from 10
patients (HG n¼ 4; NP n¼ 6), the differences in means proved
to be 5002 ng/mL, the standard deviation of means 4870 ng/
mL, leading to a required sample size of 16 women in each
group with a type II error protection of b ¼ .8. For all determi-
nations, a type I error protection of P < .05 was considered
significant. Statistical analysis was performed using Sigma Stat
Software Version 3.1 (Rockware Inc, Golden, Colorado).
Results
The demographic and clinical characteristics of the women
enrolled and the neonates are shown in Tables 1 and 2, respec-
tively. Totally, 17 women were primarily included in the HG.
Of all, 12 fulfilled the criteria of a class II, and 3 of a class I
HELLP syndrome according to the Mississippi Triple Class
System. Two patients with clinical HELLP syndrome were
retrospectively excluded, because they did not meet the
complete range of laboratory criteria. Severe hypertension
(>160/100 mm Hg) was observed in all women of the HG and
9 of 15 patients, in addition to HELLP syndrome, fulfilled the
clinical criteria of preeclampsia as recently defined by interna-
tional protocols (gestational hypertension >140/90 mm Hg, pro-
teinuria >0.3 g/24 h or protein/creatinine ratio >30 mg/mmol).30
Table 1. Demographic and Clinical Data of the Women Enrolled.a
Groups (n)
P Values
Women HG (15) NP (18) CG (10) HG vs NP HG vs CG NP vs CG
Age, years 32 (31/34) 34 (33/38) 29 (25/33) .52 .04 .01
Height, cm 170 (164/175) 170 (164/173) 169 (165/175) .67 .78 .48
Body weight prior to
pregnancy, kg
65.0 (62.5/76.0) 62.0 (60.0/65.2) 59.9 (56.2/68.1) .02 NA NA
Body weight after delivery, kg 77.0 (72.1/87.5) 76.0 (69.5/80.7) NA .08 NA NA
Gestational age at delivery,
weeks
32.0 (31.0/34.0) 39.5 (38.8/41.0) NA <.001 NA NA
Maximum blood pressure
24 hours prior to delivery,
mm Hg
173 (170/180)/99 (90/110) 127 (117/132)/70(67/75) NA <.001 NA NA
Platelet count, 109/mLb 86 (60/90) 216 (174/250) NA <.001 NA NA
AST, U/Lc 176 (101/437) 18 (17/20) NA .003 NA NA
ALT, U/Lc 160 (91/397) 13 (10/16) NA .005 NA NA
Haptoglobin, g/Ld <0.1 NA NA NA NA NA
Abbreviations: ALT, alanine transaminase; AST, aspartate aminotransferase; CG, control group; HELLP, hemolysis, elevated liver enzymes and low platelets; HG,
HELLP group; NA, not applicable; NP, normal pregnancy group.
a Data are given as median with 25th/75th percentile.
b Median was calculated from the lowest values in between 1 week prior to delivery.
c Median was calculated from the highest values in between 1 week prior to delivery.
d Of the 15 measurements, 12 were below the detection threshold of 0.1 g/L. They were calculated as 0.09 g/L.
Table 2. Clinical Data of the Neonates.a
Groups (n) HG (15) NP (18) P Values
Body weight, g 2035 (1371/2297) 3430 (3375/3520) <.001
Difference to predicted body weight, gb þ102 þ98 NA
APGAR score (points) 1/5/10 minutes postpartum 7.0/9.2/9.6 9.3/10.0/10.0 .5/.9/.9
Arterial umbilical cord pH 7.30 (7.27/7.33) 7.40 (7.32/7.41) .09
Arterial umbilical cord BE 1.1 (1.9/0.2) 4.1 (4.8/3.5) .12
Abbreviations: CG, control group; HELLP, hemolysis, elevated liver enzymes and low platelets; HG, HELLP group; NA, not applicable; NP, normal pregnancy
group.
a Data are given as median with 25th/75th percentile.
b Difference to predicted body weight (g): difference of the real body weight of the neonates to a predicted birth weight adjusted for gestational age according to
Gardosi et al, maternal height, weight, and ethnic origin are taken into account.29
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In all, 26 women were initially included in the NP. During
the course of pregnancy, 8 women were excluded (twice pre-
mature birth before week 25, 6 women decided to retreat from
the study).
The EGX Components
Changes in serum concentrations of syndecan 1, heparan sul-
fate, and hyaluronic acid during normal pregnancy are given
in Figures 1, 2, and 3, respectively. During pregnancy,
syndecan 1 levels constantly rose, especially between weeks
20 and 30 of pregnancy. Healthy women in late pregnancy
showed significantly increased serum concentrations compared
to early pregnancy (weeks 10 and 20) and controls. Heparan
sulfate serum concentrations remained nearly constant
throughout the time course. Concerning hyaluronic acid, a
moderate increase was measured between weeks 10 and 20,
leading to a significant difference between CG and NP from
week 20. In addition, we noticed a relevant intragroup differ-
ence between weeks 10 and 30 in NP.
Women with HELLP syndrome showed significantly ele-
vated serum concentrations of all EGX components compared
to both healthy pregnant women in week 30 + 3 of pregnancy
(n ¼ 15 after matching) and nonpregnant women. The corre-
sponding data are given in Table 3.
TNF-a and sTNF-Rs
Serum levels of TNF-a and its soluble receptors 1 (TNF-R1)
and 2 (TNF-R2) were measured in patients with HELLP, in
normal pregnancy week 30 + 3 (after matching) and in the
CG. Significant differences occurred in HG compared to NP
and CG in terms of sTNF-R1 and sTNF-R2. In terms of NP and
CG, only the median values of sTNF-R1 differed significantly.
Concerning TNF-a, no relevant differences among groups were
observed (Table 4).
Glucocorticoid Application
Of the 15 patients in the HG, 10 received glucocorticoids prior
to delivery. Doses of 2  12 mg of betamethasone were
administered within 48 hours. Time intervals between
Figure 1. Syndecan 1 serum concentrations during normal pregnancy.
Maternal serum concentrations of syndecan 1 during the course of
uncomplicated pregnancy (n ¼ 18). CG: nonpregnant control group.
Week 10; 20; 30; 38 (of pregnancy): gestational age of the women
enrolled. *Syndecan 1 serum concentration of CG and pregnancy weeks
10 and 20 differed significantly from week 38; P < .01 for all comparisons.
#Syndecan 1 serum concentration of CG and pregnancy weeks 10 and
20 differed significantly from week 30; P < .01 for all comparisons.
Figure 2. Heparan sulfate serum concentrations during normal preg-
nancy. Maternal serum concentrations of heparan sulfate during the
course of uncomplicated pregnancy (n ¼ 18). CG: nonpregnant control
group. Week 10; 20; 30; 38 (of pregnancy): gestational age of the women
enrolled. No significant differences among groups could be observed.
Figure 3. Hyaluronic acid serum concentrations during normal preg-
nancy. Maternal serum concentrations of hyaluronic acid during the
course of uncomplicated pregnancy (n ¼ 18). CG: nonpregnant con-
trol group. Week 10; 20; 30; 38 (of pregnancy): gestational age of the
women enrolled. *Hyaluronic acid serum concentration of CG dif-
fered significantly from weeks 20, 30, and 38; P < .05 for all compari-
sons. #Hyaluronic acid serum concentration of pregnancy week 10
differed significantly from week 30; P < .05.
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glucocorticoid medication and delivery varied according to clin-
ical requirements (1 woman <6 hours; 2 women 48-72 hours;
2 women 96-120 hours; and 5 women 7-41 days). Concerning
serum concentrations of TNF-a, sTNF-R1, and sTNF-R2, sig-
nificant differences could not be observed in these subgroups
including the group without betamethasone medication (P >
.05 for all comparisons).
Discussion
In the current study, constantly rising serum concentrations of
syndecan 1 were measured in healthy pregnant women, even
higher amounts were observed in HELLP syndrome. Signifi-
cantly, elevated serum levels of hyaluronic acid, heparan sulfate,
and sTNF-Rs were detected only in patients with HELLP,
whereas serum concentrations of TNF-a remained unchanged
compared to controls.
Maternal Serum Concentrations of EGX Components
Control group. The CG of the current study showed values
comparable to other investigations in terms of EGX compo-
nents.14,31-34 However, heparan sulfate levels of the CG
showed a greater variability than expected (Figure 2). As men-
struation is associated with a mild inflammatory response,
one cannot exclude that the stage of menstrual cycle of the
volunteers (which was not recorded) might have influenced
the results in CG.35
Uncomplicated pregnancy. Syndecan 1 serum concentrations
measured from week 30 proved to be considerably elevated
(Figure 1). Nelson et al, who investigated patients with septic
shock, noticed ‘‘only’’ an average of 246 ng/mL (range 180/
496 ng/mL).14 Because of its observational design, the current
study is not appropriate to explain this unexpected rise of EGX
components in maternal serum. However, even if pregnancy is
interpreted to be a form of controlled inflammation, a shedding
of the maternal EGX causing syndecan 1 blood levels more
than 10-fold higher than in patients with sepsis should have
triggered substantial maternal clinical symptoms and/or a vari-
ety of uncontrolled immunological reactions.14,36,37 Trans-
membrane syndecan 1 serves as a core protein of the EGX,
whereas heparan sulfate and hyaluronic acid chains are
attached to it on the luminal surface of the EGX network.2
Accordingly, an isolated rise of syndecan 1 has not yet been
reported in investigations studying EGX degradation. Elevated
levels of hyaluronic acid and/or heparan sulfate have always
been detectable, too. Different rates of renal excretion might
also have an influence on serum levels of EGX components.
However, with regard to molecular mass and charge, there is
no reason for the renal clearance of syndecan 1 to be reduced
compared to hyaluronic acid or heparan sulfate.1 Considering
these observations, sources besides the EGX have to be evalu-
ated, which might explain the presence of syndecan 1 in mater-
nal blood. We know that syndecan 1 is strongly expressed on
the apical surface of syncytiotrophoblast cells.38 The syncytio-
trophoblast is involved in the continuous process of degrada-
tion and rebuilding the placenta experiences especially
between weeks 20 and 30 of pregnancy and thus generates an
enormous turnover of cellular material.39 According to Red-
man et al, a large burden of cellular debris originating from the
placenta, especially from the syncytiotrophoblast layer, is
Table 3. Comparison of the Serum Levels of EGX Components Between HELLP Syndrome, Normal Pregnancy Week 30 + 3, and Controls
(CG).a
HG, n ¼ 15 NP week 30 + 3, n ¼ 15 CG, n ¼ 10
P Values
HG vs NP HG vs CG
Syndecan 1, ng/mL 12 252 (7369/16 595) 5943 (2637/10 292) 66.4 (50.7/69.7) .02 <.01
Heparan sulfate, mg/mL 15.8 (9.3/25.0) 4.9 (4.2/8.0) 6.2 (5.4/8.9) <.01 .01
Hyaluronic acid, ng/mL 624 (395/1314) 131 (111/168) 86.0 (82.1/93.6) <.01 <.01
Abbreviations: EGX, endothelial glycocalyx; HELLP, hemolysis, elevated liver enzymes and low platelets; HG, HELLP group; NP, normal pregnancy group.
a Data are given as median (25th/75th percentile).
Table 4. Comparison of Serum Levels of TNF-a, sTNF-R1, and sTNF-R2 Between HELLP Syndrome, Normal Pregnancy Week 30 + 3, and
Controls.a
HG, n ¼ 15 NP week 30, n ¼ 15 CG, n ¼ 10
P Values
HG vs NP HG vs CG NP vs CG
TNF-a, pg/mL 0.39 (0.35/0.49) 0.38 (0.35/0.90) 1.0 (0.38/1.26) .46 .13 .13
sTNF-R1, ng/mL 5.1 (4.3/6.3) 2.9 (2.0/3.8) 1.3 (1.2/1.5) <.001 <.01 .03
sTNF-R2, ng/mL 16.5 (9.6/22.0) 8.3 (7.4/9.9) 11.3 (7.6/13.5) .034 .03 .62
Abbreviations: CG, control group; HELLP, hemolysis, elevated liver enzymes and low platelets; HG, HELLP group; NP, normal pregnancy group; sTNF-Rs, soluble
TNF-a receptors; TNF-a, tumor necrosis factor a.
a Data are given as median (25th/75th percentile).
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released into maternal blood.40 Redman et al proposed the
presence of ‘‘syncytiotrophoblast microfragments’’ (STBM).
These are detectable in maternal serum in normal pregnancy
as well as in preeclampsia.41 Goswami et al quantified the
maternal serum concentrations of these STBM to be about 16
ng/mL in normal pregnancy and 41 ng/mL in early onset pre-
eclampsia.42 We now propose glycocalyx components like syn-
decan 1 to be a major fraction of STBM and that the amount of
these components pervading the maternal circulation is much
greater than has previously been assumed. It has been shown
that disrupted glycocalyx fragments can activate leukocytes,
which, on the other hand, are able to cleave heparan sulfate
from syndecans of the EGX.43,44 However, whether a fraction
of the ‘‘syndecan 1 burden’’ is deriving directly from the mater-
nal EGX cannot be decided on the basis of the current data.
HELLP syndrome. In HG, serum levels of syndecan 1 were
nearly twice as high as in NP (P ¼ .02). Interestingly, Jokimaa
et al showed a decreased syndecan 1 expression on the chorio-
nic villi of preeclamptic patients.45 This, on first sight, speaks
against a placental origin of elevated syndecan 1 serum concen-
trations measured in the HG. However, the diminished expres-
sion of syndecan 1 observed by Jokimaa et al might as well
have been caused by an increased loss of syndecan 1 into the
maternal vasculature as by a reduced placental syndecan 1
‘‘production.’’ Increased syndecan 1 levels in the HG were
accompanied by significantly elevated hyaluronic acid and
heparan sulfate concentrations (6-fold and 3-fold, respectively)
The presence of all 3 measured glycocalyx components in
maternal blood would be in better accordance with a maternal
endothelial origin, but as in NP, the current data do not allow
definitive conclusions to be drawn concerning the source.
Despite proteinuria, laboratory measurements did not signalize
renal injury in HG and all but 1 patient displayed a creatinine
clearance of more than 120 mL/min (data not shown). Thus,
similar to NP, there is no obvious reason for EGX serum levels
to be elevated because of a potential kidney malfunction.
Finally, one has to consider whether arterial hypertension may
have induced EGX deterioration in patients with HELLP.
According to previous studies, hypertension does not directly
provoke endothelial shear stress.46,47 However, according to
Borghi et al, hypertension in pregnancy can be associated
with elevated levels of atrial natriuretic peptide (ANP) which
in turn has shown to cause an EGX shedding in isolated
arteries of guinea pigs.48,49 Because ANP concentrations were
not measured, the relevance of these in vitro findings in con-
text with the current study remains unclear.
TNF-a and sTNF-Rs
Study results concerning serum levels of TNF-a in preeclamp-
sia are inconsistent. Many, but not all studies report maternal
TNF-a concentrations as elevated.50-55 Failure to detect TNF-
a can occur, if time requirements for processing samples are
too long with regard to the short biological half-life of TNF-a
(<5 minutes).55 Acquisition time may also have been a problem
in the current study.
Serum concentrations of sTNF-Rs are considered reliable
markers for inflammation, having longer half-lives than the
ligand.56 We observed a significant difference in sTNF-R1 and
sTNF-R2 concentrations in women with HELLP syndrome
compared to NP and controls. To our knowledge, increased
levels of those receptors have only been described for pree-
clampsia but have not yet been demonstrated for HELLP
syndrome.52,56 Glucocorticoid treatment can influence TNF-a
and its soluble receptors in different ways: TNF-a and
sTNF-R2 production can be inhibited, whereas sTNF-R1 expres-
sion is known to be increased. However, the effect of dexa-
methasone on all these mediators does not exceed an interval
longer than 24 hours after glucocorticoid administration and,
therefore, should not have influenced cytokine serum concentra-
tions in the current study.57-59 Syndecan 1 serum levels were sig-
nificantly correlated to TNF-a (r¼ 0.60, P¼ .02), sTNF-R1 (r¼
0.67, P < .01), and sTNF-R2 (r ¼ 0.59, P ¼ .02) in patients with
HELLP, but not in NP. A relevant correlation between these
cytokines and the other EGX components could not be observed.
Thus, data do not clearly demonstrate a relationship between
these mediators and an EGX shedding but do speak in favor of
an exaggerated inflammatory response in the concerned women.
To date, most investigators consider HELLP syndrome to be
associated with preeclampsia. Accordingly, 60% of the patients
in HG fulfilled the diagnostic criteria valid for preeclampsia.
Nevertheless, preeclamptic women without HELLP syndrome
were not included for the following reasons: today preeclamp-
sia is well defined by international protocols.29,60 However,
these protocols usually leave space for a variety of clinical
manifestations and are partially independent from the severity
of the disease. Therefore, integrating solely preeclamptic
women probably would have led to an inhomogeneous study
population and thus complicating the interpretation of results.
In contrast, HELLP syndrome is clearly defined by a set of
laboratory values and the concerned women definitely display
severe clinical symptoms. Therefore, it seemed advantageous
to include only women with HELLP syndrome in the current
study, even if this led to relatively small study groups.
Conclusion
A shedding of the maternal EGX has not yet been described in
pregnancy nor has the placenta been considered as a source of
glycocalyx fragments. The current study demonstrates that
glycosaminoglycans pervading the maternal circulation may
play a role in normal pregnancy as well as in HELLP syn-
drome. Whether the maternal endothelium, the placenta, or
other organic structures have to be regarded as the origin of
glycocalyx components in maternal serum will have to be
investigated in further studies.
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